Deborah Keller Tanner biography
Deborah L. V. Keller Tanner serves as Independent Director of the Company. Ms. Keller serves as a Principal at Black Frame Advisors, LLC, having recently retired as CEO of Covance Drug Development—a business segment of Laboratory Corporation of America Holdings. Prior to serving as CEO, Ms. Keller spent more than 28 years at Covance in several leadership roles, including Corporate Executive Vice President and Group President of Research and Development Laboratories, Corporate Senior Vice President and President of Discovery and Translational Services, and Vice President of Analytical Services in Europe. She is a trustee of the Wisconsin Alumni Research Foundation, Operating Partner of HealthCloud Capital Fund and serves on the Dean's Advisory Board for the University of Wisconsin School of Business, where she is also an adjunct professor. Ms. Keller was named one of FierceBiotech's 10 Top Women in Biotech in 2012.
What is the salary of Deborah Tanner?
As the Independent Director of West Pharmaceutical Services, the total compensation of Deborah Tanner at West Pharmaceutical Services is $283,862. There are 18 executives at West Pharmaceutical Services getting paid more, with Eric Green having the highest compensation of $6,533,690.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
How old is Deborah Tanner?
Deborah Tanner is 57, she's been the Independent Director of West Pharmaceutical Services since 2017. There are 10 older and 16 younger executives at West Pharmaceutical Services. The oldest executive at West Pharmaceutical Services, Inc. is Patrick Zenner, 73, who is the Independent Chairman of the Board.
What's Deborah Tanner's mailing address?
Deborah's mailing address filed with the SEC is 530 HERMAN O. WEST DRIVE, , EXTON, PA, 19341.
Insiders trading at West Pharmaceutical Services
Over the last 19 years, insiders at West Pharmaceutical Services have traded over $32,829,857 worth of West Pharmaceutical Services stock and bought 19,924 units worth $1,139,950 . The most active insiders traders include Robert F Friel, Paolo Pucci, eDouglas A Michels. On average, West Pharmaceutical Services executives and independent directors trade stock every 40 days with the average trade being worth of $4,786,805. The most recent stock trade was executed by Charles Witherspoon on 19 August 2024, trading 1,029 units of WST stock currently worth $308,700.
What does West Pharmaceutical Services do?
west works side-by-side with healthcare partners from concept to the patient, designing and manufacturing packaging and delivery systems that promote efficiency, reliability and safety. west leads the way with cutting-edge technologies and quality systems, a thorough understanding of global regulatory compliance, and an unmatched knowledge of relevant pharmaceutical product testing, development and packaging. west supports customers from sales, manufacturing, and research and development locations in north and south america, europe, asia and australia.
What does West Pharmaceutical Services's logo look like?
West Pharmaceutical Services executives and stock owners
West Pharmaceutical Services executives and other stock owners filed with the SEC include:
-
Eric Green,
President, Chief Executive Officer, Director -
Eric M. Green,
Pres, CEO & Director -
Bernard Birkett,
Chief Financial Officer, Senior Vice President -
George Miller,
Senior Vice President, General Counsel, Corporate Secretary -
Bernard J. Birkett,
Sr. VP & CFO -
Silji Abraham,
Senior Vice President and Chief Digital and Transformation Officer -
David Montecalvo,
Senior Vice President, Chief Operating and Supply Chain Officer -
Annette Favorite,
Chief Human Resource Officer, Senior Vice President -
David A. Montecalvo,
Sr. VP and Chief Operations & Supply Chain Officer -
Silji Abraham,
Sr. VP & Chief Technology Officer -
Patrick Zenner,
Independent Chairman of the Board -
Douglas Michels,
Independent Director -
Thomas Hofmann,
Independent Director -
Paula Johnson,
Independent Director -
William Feehery,
Independent Director -
Mark Buthman,
Independent Director -
Myla Lai-Goldman,
Independent Director -
Paolo Pucci,
Independent Director -
Deborah Keller Tanner,
Independent Director -
Chad Winters,
Chief Accounting Officer, Principal Accounting Officer, Vice President, Controller -
Robert Friel,
Independent Director -
Cindy Reiss-Clark,
Senior Vice President of Global Market Units and Commercial Solutions -
Quintin Lai,
Vice President - Corporate Development, Strategy and Investor Relations -
Eric Resnick,
Chief Technology Officer, Vice President -
Richard D. Luzzi,
Sr. VP of HR -
Annette F. Favorite,
Chief HR Officer & Sr. VP -
Michele Polinsky,
VP of Global Communications -
Kimberly Banks MacKay,
Sr. VP, Gen. Counsel & Company Sec. -
Dr. Quintin J. Lai C.F.A., Ph.D.,
VP of Strategy & Investor Relations -
Daniel Malone,
Vice President & Controller -
William J Federici,
VP & CFO -
John H Weiland,
Director -
Karen Flynn,
President, America's Region -
Heino Lennartz,
President Europe -
Anthony Welters,
Director -
Warwick Bedwell,
VP Pharma Pkgs Systems Asia Pa -
John E Paproski,
Vice President-Innovations -
Christopher G Ryan,
President, PPS, Americas -
Rachael M Bushey,
VP, Deputy Gen Coun & Corp Sec -
Jeffrey C Hunt,
VP Pharma Pckg Systems -
John R Gailey,
VP, Gen. Counsel & Sec. -
Richard D Luzzi,
VP, Human Resourses -
L Robert Johnson,
Director -
Michael A Anderson,
Vice President & Treasurer -
Donald E Jr Morel,
Chairman of the Board & CEO -
Robert C Young,
Director -
Donald A Mc Millan,
President Pharma Systems NA -
Steven A Ellers,
Pres., Pharma. Systems Div. -
Geoffrey F Worden,
Director -
John P Neafsey,
Director -
Joseph E Abbott,
Corporate Controller -
Dijk Ronald Van,
President Asia Pacific -
Robert S Hargesheimer,
President-The Tech Group -
Fabio De Sampaio Doria Filho,
Pres., Europe & Asia Pacific -
Matthew T Mullarkey,
Chief Operating Officer -
Robert J Keating,
Pres., Europe & Asia Pacific -
Jenne K Britell,
Director -
Herbert L Hugill,
Pres. of the Americas, Pharma. -
Linda R Altemus,
VP & Chief Compliance Officer -
Molly Joseph,
Director -
Deborah L Keller,
Director -
Stephen H Lockhart,
Director -
Charles Witherspoon,
VP & Treasurer -
Kimberly Banks Mac Kay,
SVP, GC & Corporate Secretary